Sponsor: Genmab
Sponsor Study ID: GCT3013-01
Study Title: A Phase 1/2, Open Label, Dose Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B Cell Lymphoma
CTO #: 103260
NCT Number: NCT03625037
Phase: I/II
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Non-Hodgkin's Lymphoma
Study Objectives: The trial is an open-label, multi-center safety trial of GEN3013 (DuoBody®-CD3xCD20). The trial consists of two parts: a dose escalation part (phase 1, first-in-human (FIH) and an expansion part phase 2a). The expansion part of the trial will be initiated once the Recommended Phase 2 Dose (RP2D) has been determined.